New drug for Post-Transplant CMV infection under Real-World review
NCT ID NCT06555432
First seen Nov 18, 2025 · Last updated May 25, 2026 · Updated 24 times
Summary
This study looks at how safe and effective the drug LIVTENCITY (Maribavir) is for treating cytomegalovirus (CMV) infection in adults who have had an organ or stem cell transplant. About 168 participants in South Korea will be followed for 20 weeks during their routine care. The goal is to confirm the drug works well in everyday medical practice and to track any side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CYTOMEGALOVIRUS (CMV) are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
The Catholic University of Korea, Seoul ST. Mary's Hospital
RECRUITINGSeoul, 06591, South Korea
Contact
Contact Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.